Vivos Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.38 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-11-19
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-06-30 was $2.38, a 76.78% decline year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-06-30 was $10.25.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.23, a 30.27% decline year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.50, a 0.00% change year-over-year.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.01, a 80.69% decline from fiscal 2021.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $5.23, a 30.27% decline from fiscal 2020.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $7.50, a 0.00% change from fiscal 2019.
- Vivos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $7.50.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.38 10-Q · filed 2025-11-19 | |||
| 2024-06-30 | $2.38 10-Q · filed 2024-08-14 | $2.38 10-Q · filed 2024-08-14 | ||
| 2023-09-30 | $10.00 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $10.25 10-Q · filed 2024-08-14 | $10.25 10-Q · filed 2024-08-14 | ||
| 2022-12-31 | $1.01 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $2.30 10-Q · filed 2022-12-20 | |||
| 2022-06-30 | $2.32 10-Q · filed 2022-12-20 | |||
| 2022-03-31 | $5.23 10-Q/A · filed 2022-11-25 | |||
| 2021-12-31 | $5.23 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $5.23 10-Q · filed 2022-12-20 | |||
| 2021-06-30 | $6.27 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $7.50 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $7.50 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $7.50 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $7.50 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $7.50 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $7.50 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |